14 Dec 22
14 Dec 22
A year of record sales and company growth

Winner of two Queen’s Awards for Enterprise in Innovation and International Trade

Highest year-on-year sales growth in the company’s 25-year history

Keele, UK, 14 December 2022 – Biocomposites, an international medical devices company that engineers, manufactures and…...
29 Nov 22
29 Nov 22
Biocomposites adds Mexico to its list of countries where STIMULAN is approved as an antibiotic carrier for use in bone and soft tissue
STIMULAN® gives surgeons the freedom to choose and combine the antibiotics that support their infection treatment strategy
Keele, UK, 29 November 2022 – Biocomposites, an international medical devices company that engineers, manufactures and…...
3 Nov 22
3 Nov 22
Biocomposites to host Infection Management Symposium on new best practice framework for treating diabetic foot infections at Wounds UK
• Consensus group of clinicians have developed a framework of best practice and toolkit for podiatrists treating diabetic foot infections
• STIMULAN placed in foot wounds following debridement can release antibiotics at therapeutic concentrations
Keele, UK, 3 November 2022 – Biocomposites, an international medical devices company that engineers, manufactures and…...
Introducing STIMULAN® to
Podiatrists and Tissue Viability Nurses

Diabetic foot osteomyelitis and diabetic foot ulcers
can be challenging to heal. Find out how STIMULAN can help.


The only calcium matrix approved for mixing with vancomycin, gentamicin and tobramycin for use in bone and soft tissue.

Explore our library

Our industry leading knowledge, dedication and experience is supported with over 400 peer
reviewed papers, presentations and posters.

Pioneering calcium compounds

Innovation is at the very heart of what we do, resulting in over 100 grants and registrations.

Your specialty

Access case studies, clinical and pre-clinical papers for musculoskeletal infection, trauma and spine to see how we are innovating across a wide range of clinical applications to help surgeons and their patients.

Musculoskeletal infections

Musculoskeletal infections, including infected non-unions, osteomyelitis and periprosthetic joint infections, are one of the biggest healthcare challenges of the 21st century.

As the rapid growth of antibiotic-resistant strains and biofilms continues to outpace the development of new antibiotics and antibiotic strategies, care delivery is becoming increasingly challenging and complicated.


The popularity of spine surgery differs around the world. The number of procedures performed in the USA is double the number performed in Western Europe, Canada and Australia combined, and five times the number in the UK.

In the USA, the number of spinal fusion procedures increased by 64% between 2002 and 2014, from approximately 268,000 to 414,000. The average cost per procedure has increased from $15,868 to $28,954 over the same period and was more than $12 billion in total in 2014.

Why Biocomposites?

At Biocomposites, we are pioneering calcium compound devices to regenerate and repair bone and soft tissue. With over 30 years’ experience of manipulating the surface chemistry and crystalline properties of calcium compounds, we engineer and manufacture products at the forefront of calcium technology.

  • Singular focus
  • Proprietary technology
  • Dedicated to quality
Learn more